Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The follow up study of "Phase l / ll Study of S-1+oxaliplatin (SOX)+cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type (JACCRO CC-06)".

Trial Profile

The follow up study of "Phase l / ll Study of S-1+oxaliplatin (SOX)+cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type (JACCRO CC-06)".

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2018

At a glance

  • Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms JACCRO CC-06 B
  • Most Recent Events

    • 17 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 21 Apr 2017 New trial record
    • 17 Apr 2017 According to UMIN, the date for data entry closure is 30/06/2017, and the date for conclusion of data analysis is 31/07/2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top